Pear Therapeutics to offer its digital therapeutics through telehealth partners
The company's first telehealth offering is with PursueCare to offer patients an end-to-end virtual continuum of comprehensive addiction recovery care.
Pear Therapeutics ended 2021 with $4.2M in revenue, expects $22M this year
Yes, the digital therapeutics market is taking off...
Digital therapeutics company Pear Therapeutics to go public in a $1.6B SPAC deal
The deal provides additional investment to capitalize on Pear's position by investing in the commercialization of its three FDA-authorized products.
Pear Therapeutics licenses multiple technologies to bolster its PDT platform
The company has expanded its platform with digital biomarkers, machine learning algorithms and sensor-based technologies.
Pear Therapeutics launches Somryst for chronic insomnia
Somryst is the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia.
Pear Therapeutics publishes real-world utilization data for reSET-O
Near-term reductions in medical costs after prescription of reSET-O exceeded the amount needed to offset the cost of the product.
PreferredOne taps Pear to become the first health plan to cover digital therapeutics
PreferredOne will provide broad patient access and reimbursement for reSET and reSET-O for people with substance use disorder and opioid use disorder.
Sandoz, Pear Therapeutics launch reSET to treat SUD patients
Adding reSET to outpatient therapy significantly improved abstinence in substances of abuse and treatment retention compared to standard of care alone.
Magellan Health to pilot PEAR Therapeutics’ digital therapeutic reSET
The pilot program will enroll 250 patients with Substance Use Disorders (SUD) and offer each patient a 12-week course of reSET therapy.
Pear Therapeutics gets $20M for its prescription digital therapies
The company will use the money to build and launch a portfolio of eFormulations, including reSET and reSET-O, for treating substance use disorder.